# Ainsley Ross

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/ainsley-ross/

## Facts

| Field | Value |
| --- | --- |
| Citations | 365 |
| Field | Glioma Diagnosis and Treatment |
| h-index | 5 |
| i10-index | 4 |
| Last Known Institution | CRISPR Therapeutics (Switzerland) |
| OpenAlex ID | https://openalex.org/A5002415811 |
| Works | 12 |

## Researcher papers

- [An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma](https://scholariq.org/papers/an-exploratory-survival-analysis-of-anti-angiogenic-therapy-for-recurrent/)
- [Sickle cell vaso-occlusion causes activation of iNKT cells that is decreased by the adenosine A2A receptor agonist regadenoson](https://scholariq.org/papers/sickle-cell-vaso-occlusion-causes-activation-of-inkt-cells-that-is-decreased-by/)
- [Comparative rates of adverse events with different formulations of intravenous iron](https://scholariq.org/papers/comparative-rates-of-adverse-events-with-different-formulations-of-intravenous/)
- [CTX110 Allogeneic CRISPR-Cas9-Engineered CAR T Cells in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 1 Dose Escalation Carbon Study](https://scholariq.org/papers/ctx110-allogeneic-crispr-cas9-engineered-car-t-cells-in-patients-pts-with/)
- [Sickle cell disease (SCD), iNKT cells, and regadenoson infusion.](https://scholariq.org/papers/sickle-cell-disease-scd-inkt-cells-and-regadenoson-infusion/)
- [Phase I open-label, ascending dose trial of AGEN1884, an anti-CTLA-4 monoclonal antibody, in advanced solid malignancies: Dose selection for combination with PD-1 blockade.](https://scholariq.org/papers/phase-i-open-label-ascending-dose-trial-of-agen1884-an-anti-ctla-4-monoclonal/)
- [120 A Novel Combinatorial Treatment for Glioblastoma of Temozolomide and JLK1486](https://scholariq.org/papers/120-a-novel-combinatorial-treatment-for-glioblastoma-of-temozolomide-and-jlk1486/)
- [Phase 1 open-label, multiple ascending dose trial of AGEN1884, an anti-CTLA-4 monoclonal antibody, in advanced solid malignancies.](https://scholariq.org/papers/phase-1-open-label-multiple-ascending-dose-trial-of-agen1884-an-anti-ctla-4/)
- [89 Temozolomide treatment combined with Notch inhibition blocks recovery of glioma cells through the induction of senescence](https://scholariq.org/papers/89-temozolomide-treatment-combined-with-notch-inhibition-blocks-recovery-of/)
- [38 Characterizing Glioblastoma-derived Endothelial Cells](https://scholariq.org/papers/38-characterizing-glioblastoma-derived-endothelial-cells/)

## Researcher topics

- [Glioma Diagnosis and Treatment](https://scholariq.org/topics/glioma-diagnosis-and-treatment/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)
- [Hemoglobinopathies and Related Disorders](https://scholariq.org/topics/hemoglobinopathies-and-related-disorders/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Immune Cell Function and Interaction](https://scholariq.org/topics/immune-cell-function-and-interaction/)

## Researcher university

- [CRISPR Therapeutics (Switzerland)](https://scholariq.org/institutions/crispr-therapeutics-switzerland/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.